Patents by Inventor David B. Lebo

David B. Lebo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11351121
    Abstract: An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 7, 2022
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: David B. Lebo, Suzan Owaisat
  • Publication number: 20210212994
    Abstract: The invention provides an econazole nitrate and thiourea medical patch for the treatment of nail and skin onychomycosis, achieving improved drug penetration, and thus allowing more drug to penetrate into the nail bed and reach the minimum inhibitory concentration.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 15, 2021
    Inventors: David B. Lebo, Cong Li
  • Patent number: 10994013
    Abstract: Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 4, 2021
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Kalpana N. Thakare, David B. Lebo
  • Publication number: 20190321298
    Abstract: An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Inventors: David B. Lebo, Suzan Owaisat
  • Patent number: 10383825
    Abstract: An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 20, 2019
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: David B. Lebo, Suzan Owaisat
  • Publication number: 20170042820
    Abstract: An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.
    Type: Application
    Filed: August 12, 2016
    Publication date: February 16, 2017
    Inventors: David B. Lebo, Suzan Owaisat
  • Publication number: 20160058868
    Abstract: Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 3, 2016
    Inventors: KALPANA N. THAKARE, DAVID B. LEBO
  • Publication number: 20110087153
    Abstract: Iontophoretic patches for the delivery of rizatriptan and methods of using the patches are described.
    Type: Application
    Filed: October 12, 2010
    Publication date: April 14, 2011
    Inventors: Angel S. ANGELOV, David B. LEBO
  • Publication number: 20030055107
    Abstract: A pharmaceutical composition comprising a pharmaceutically active agent and a salt of said pharmaceutically active agent with the proviso that said composition does not contain hydrolyzed cellulose, wherein said pharmaceutical active agent is a weak acid or weak base. The present invention is also directed to a new ibuprofen form having, when potassium is present in said form as a counter ion, an IR peak at 1706 cm−1 shifted and broadened in absorbance relative to racemic ibuprofen free acid, the form's characteristic absorbance profile from 1000 to 650 cm−1 and broadened in absorbance relative to racemic ibuprofen free acid, the form's characteristic absorbance profile from 1000 to 650 cm−1 and D-spacings of 21.1, 7.1, and 3.4 Å by X-ray diffraction.
    Type: Application
    Filed: March 27, 2002
    Publication date: March 20, 2003
    Inventors: Xinmin Samuel Xu, David F. Erkoboni, David B. Lebo